Pharmacokinetic parameters and a theoretical study about metabolism of BR-AEA (a salbutamol derivative) in rabbit

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 25, Issue 3, 2010, Pages 340-346

  Soriano Ursúa, Marvin Antonio ^a   Correa Basurto, Jose ^a   Romero Huerta, Juan ^a   Elizalde Solis, Octavio ^a   Galicia Luna, Luis Alejandro ^a   Trujillo Ferrara, Jose Guadalupe ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

2 adrenoceptor agonist; Boron; Pharmacokinetic parameters; Salbutamol derivative; Sulfotransferases

Indexed keywords

1 (4 DIHYDROXY 3,5 DIOXA 4 BORABICYCLO[4.4.0]DECA 7,9,11 TRIEN 9 YL) 2 (TERT BUTYLAMINO)ETHANOL; ADRENALIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BORONIC ACID DERIVATIVE; DOPAMINE; HYDROXYL GROUP; SALBUTAMOL; SERINE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A3; SULFOTRANSFERASE 1C1; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVE SITE; MALE; MOLECULAR DOCKING; NONHUMAN; PARAMETER; PRIORITY JOURNAL; RABBIT; REPRODUCIBILITY; SIMULATION; SINGLE DRUG DOSE; SULFATION;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; HALF-LIFE; METABOLISM; MODELS, THEORETICAL; PHARMACOKINETICS; PROTEIN BINDING; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFOTRANSFERASES;

ORYCTOLAGUS CUNICULUS;

EID: 77951471607     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756360903179450     Document Type: Article

References (31)

1. Fitzgerald MA. Managing bronchospasm with short-acting beta(2)-agonists. Nurse Pract 2006;31:47-53.
2. 2-adrenergic receptor agonists in patients with type 1 diabetes mellitus and hypoglycemia unawareness. J Clin Endocrinol Metab 2006;91:2878-2884
3. van Baak MA, Mayer LH, Kempinski RE, Hartgens F. Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men. Med Sci Sports Exerc 2000;32:1300-1306
4. Burgraaf J, Westendorp RG, in't Veen JC, Schoemaker RC, Sterk PJ, Cohen AF, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2000;56:567-569
5. Raghunathan K, Nagajothi N. Paradoxical bronchospasm: a potentially life threatening adverse effect of salbutamol. South Med J 2006;99:288-289
6. Janson C, Boe J, Boman G, Mossberg B, Svedmyr N. Bronchodilator intake and plasma levels on admission for severe acute asthma. Eur Respir J 1992;5:80-85
7. Anderson PJ, Zhou X, Breen P, Gann L, Logsdon TW, Compadre CM, et al. Pharmacokinetics of (R,S)-salbutamol after aerosol inhalation in healthy adult volunteers. J Pharm Sci 1998;87:841-844
8. Perreault S, Dumont L, Villiere V, Ong H, Adam A, du Souich P. Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. Drug Metab Dispos 1993;21:485-491
9. Boulton DW, Fawcett JP. The pharmacokinetics of levosalbutamol: what are the clinical implications? Clin Pharmacokinet 2001;40:23-40.
10. Dombrovski L, Dong A, Bochkarev A, Plotnikov AN. Crystal structures of human sulfotransferases SULT1B1and SULT1C1 complexed with the cofactor product adenosine-3-5-diphosphate (PAP). Proteins 2006;64:1091-1094
11. Riley E, Bolton-Grob R, Liyou N, Wong C, Tresillian M, McManus ME. Isolation and characterization of a novel rabbit sulfotransferase isoform belonging to the SULT1A subfamily. Int J Biochem Cell Biol 2002;34:958-969
12. Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 1986;22:587-593
13. 2 adrenoceptor agonist. Eur J Med Chem 2009;44:2840-2846
14. Tafi A, Agamennone M, Tortorella P, Alcaro S, Gallina C, Botta M. AMBER force field implementation of the boronate function to simulate the inhibition of β-lactamases by alkyl and aryl boronic acids. Eur J Med Chem 2005;40:1134-1142
15. Miller LG, Greenblatt DJ. Determination of salbutamol in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1986;381:205-208
16. Smith DJ. The pharmacokinetics, metabolism, and tissue residues of β-adrenergic agonists in livestock. J Anim Sci 1998;76:173-194
17. Shao F, Wang G, Xie H, Zhu X, Sun JA. Pharmacokinetic study of triptolide, a constituent of immunosuppressive Chinese herb medicine in rats. Biol Pharm Bull 2007;30:702-707
18. Perreault S, Ong H, Du Souich P. Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. J Pharmacokinet Biopharm 1992;20:461-476
19. Frisch MJ, et al. GAUSSIAN 98, Revision A.9. Pittsburgh, PA:Gaussian, Inc., 1998.
20. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 1998; 19:1639-1662
21. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003;31:3381-3385
22. Guex N, Peitsch MC. Swiss Model and the Swiss-PDBViewer: an environment for comparative protein modeling. Electrophoresis 1997;18:2714-2723
23. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33-38
24. Han Y, Lv Z, Jiang T, Wang Y. Bioanalysis and pharmacokinetics of chitosan ester in rabbit serum by HPLC with postcolumn fluorescence derivatization. J Chromatogr B 2007;845:138-142
25. Dajani R, Hood AM, Coughtri MWH. A single amino acid, Glu146, governs the substrate specificity of a human dopamine sulfotransferase, SULT1A3. Mol Pharm 1998;54:942-948
26. Walle UK, Pesola GR, Walle T. Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Br J Clin Pharmacol 1993;35:413-418
27. Tsoi C, Widersten M, Morgenstern R, Swedmark S. Amino acid residue 247 in canine sulfotransferase SULT1D1: a new determinant of substrate selectivity. Biochem J 2004;378:687-692
28. Pacifici GM. Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: a review of the literature. Int J Clin Pharmacol Ther 2004;42:488-495
29. Barnett AC, Tsvetanov S, Gamage N, Martin JL, Duggleby RG, McManus ME. Active site mutations and substrate inhibition in human sulfotransferase 1A1 and 1A3. J Biol Chem 2004;279:18799-18805
30. Romero-Huerta J. Síntesis, caracterización y evaluación de la farmacocinética del borato de R-ariletilamina en conejo. Master's Thesis, Escuela Superior de Medicina-IPN, México, 2006.
31. Feakes DA, Shelly K, Hawthorne MF. Selective boron delivery to murine tumors by lipophilic species incorporated in the membranes of unilamellar liposomes. Proc Natl Acad Sci 1995;92:1367-1370